Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).

Abdulghani J, Gokare P, Gallant JN, Dicker D, Whitcomb T, Cooper T, Liao J, Derr J, Liu J, Goldenberg D, Finnberg NK, El-Deiry WS.

Clin Cancer Res. 2016 Dec 15;22(24):6192-6203. Epub 2016 Jun 15.

2.

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, Leiby B, Hoang DT, Mirtti T, Alanen K, Zinda M, Huszar D, Nevalainen MT.

Mol Cancer Ther. 2014 May;13(5):1246-58. doi: 10.1158/1535-7163.MCT-13-0605. Epub 2014 Feb 27.

3.

Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.

Abdulghani J, Allen JE, Dicker DT, Liu YY, Goldenberg D, Smith CD, Humphreys R, El-Deiry WS.

PLoS One. 2013 Sep 26;8(9):e75414. doi: 10.1371/journal.pone.0075414. eCollection 2013.

4.

Impact of genetic targets on prostate cancer therapy.

Sheikh H, Abdulghani J, Ali S, Sinha R, Lipton A.

Adv Exp Med Biol. 2013;779:359-83. doi: 10.1007/978-1-4614-6176-0_17. Review.

PMID:
23288649
5.

Molecular and genetic markers of follicular-cell thyroid cancer: etiology and diagnostic and therapeutic opportunities.

Goyal N, Setabutr D, Abdulghani J, Goldenberg D.

Adv Exp Med Biol. 2013;779:309-26. doi: 10.1007/978-1-4614-6176-0_14. Review.

PMID:
23288646
6.

Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific death in patients treated by radical prostatectomy.

Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A, Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen MT.

Hum Pathol. 2013 Mar;44(3):310-9. doi: 10.1016/j.humpath.2012.06.001. Epub 2012 Sep 29.

7.

Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.

Wang W, Gallant JN, Katz SI, Dolloff NG, Smith CD, Abdulghani J, Allen JE, Dicker DT, Hong B, Navaraj A, El-Deiry WS.

Cancer Biol Ther. 2011 Aug 1;12(3):229-38. Epub 2011 Aug 1.

PMID:
21725212
8.

TRAIL receptor signaling and therapeutics.

Abdulghani J, El-Deiry WS.

Expert Opin Ther Targets. 2010 Oct;14(10):1091-108. doi: 10.1517/14728222.2010.519701. Review.

PMID:
20819019
9.

Stat3 promotes metastatic progression of prostate cancer.

Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, Lisanti MP, Zellweger T, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Nevalainen MT.

Am J Pathol. 2008 Jun;172(6):1717-28. doi: 10.2353/ajpath.2008.071054. Epub 2008 May 15.

10.

Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells.

Tan SH, Dagvadorj A, Shen F, Gu L, Liao Z, Abdulghani J, Zhang Y, Gelmann EP, Zellweger T, Culig Z, Visakorpi T, Bubendorf L, Kirken RA, Karras J, Nevalainen MT.

Cancer Res. 2008 Jan 1;68(1):236-48. doi: 10.1158/0008-5472.CAN-07-2972.

11.

Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway.

Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT.

Endocrinology. 2007 Jul;148(7):3089-101. Epub 2007 Apr 5.

PMID:
17412813
12.

A type II ribonuclease H from Leishmania mitochondria: an enzyme essential for the growth of the parasite.

Misra S, Bennett J, Friew YN, Abdulghani J, Irvin-Wilson CV, Tripathi MK, Williams S, Chaudhuri M, Chaudhuri G.

Mol Biochem Parasitol. 2005 Oct;143(2):135-45.

Supplemental Content

Loading ...
Support Center